Trade Bristol Myers ^BMY

Fort Washington Investment Advisors Inc. OH Buys 18,876 Shares of Bristol-Myers Squibb (NYSE:BMY)

Davis Investment Partners LLC Boosts Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

BioNTech to acquire CureVac in $1.25 billion all-stock deal

Wedge Capital Management L L P NC Sells 511,384 Shares of Bristol-Myers Squibb (NYSE:BMY)

Curbstone Financial Management Corp Boosts Stake in Bristol-Myers Squibb (NYSE:BMY)

Franklin Street Advisors Inc. NC Buys 8,191 Shares of Bristol-Myers Squibb (NYSE:BMY)

CX Institutional Sells 8,445 Shares of Bristol-Myers Squibb (NYSE:BMY)

Farther Finance Advisors LLC Acquires 13,372 Shares of Bristol-Myers Squibb (NYSE:BMY)

Philochem, BMS ink $1.35B deal for prostate cancer candidate OncoACp3 | BioWorld

Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties | Morningstar

Handelsbanken Fonder AB Purchases 6,956 Shares of Bristol-Myers Squibb (NYSE:BMY)

224,806 Shares in Bristol-Myers Squibb (NYSE:BMY) Bought by Nepsis Inc.

Abacus FCF Advisors LLC Grows Stock Position in Bristol-Myers Squibb (NYSE:BMY)

Park Avenue Securities LLC Acquires 9,973 Shares of Bristol-Myers Squibb (NYSE:BMY)

CHICAGO TRUST Co NA Acquires 7,890 Shares of Bristol-Myers Squibb (NYSE:BMY)

Toth Financial Advisory Corp Grows Holdings in Bristol-Myers Squibb (NYSE:BMY)

Greystone Financial Group LLC Makes New $9.76 Million Investment in Bristol-Myers Squibb (NYSE:BMY)

Vest Financial LLC Increases Stock Position in Bristol-Myers Squibb (NYSE:BMY)

Capital Investment Advisors LLC Has $14.01 Million Holdings in Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by UMB Bank n.a.

Bristol-Myers Squibb (NYSE:BMY) Stock Holdings Cut by Bourne Lent Asset Management Inc.

Procyon Advisors LLC Purchases 9,763 Shares of Bristol-Myers Squibb (NYSE:BMY)

Hennion & Walsh Asset Management Inc. Has $1.06 Million Holdings in Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb (NYSE:BMY) Receives Consensus Recommendation of "Hold" from Brokerages

Wall Street Zen Downgrades Bristol-Myers Squibb (NYSE:BMY) to Buy

Was Jim Cramer Right About Bristol-Myers Squibb Co. (BMY)?

Denovo Biopharma Announces Formation of Neuroscience Scientific Advisory Board to Advance Precision Medicine in Depression | Morningstar

Generali Investments Management Co LLC Increases Stake in Bristol-Myers Squibb (NYSE:BMY)

Genetic mutation identified as key factor in immunotherapy resistance for melanoma

RFG Advisory LLC Buys 11,208 Shares of Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb (NYSE:BMY) Shares Bought by Merit Financial Group LLC

NBC Securities Inc. Has $623,000 Holdings in Bristol-Myers Squibb (NYSE:BMY)

Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma

TruWealth Advisors LLC Buys New Stake in Bristol-Myers Squibb (NYSE:BMY)

Contravisory Investment Management Inc. Acquires 127,239 Shares of Bristol-Myers Squibb (NYSE:BMY)

Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial

Undetectable Disease Status in Myeloma Similar With Drug Therapy, Transplantation

Truist Lifts BioNTech (BNTX) Price Target After New Partnership

Bristol-Myers Squibb (NYSE:BMY) Collaborates With BioNTech For Antibody Development In Cancer Treatment

Bristol-Myers Squibb (NYSE:BMY) Stake Raised by Viking Fund Management LLC

Fulton Bank N.A. Reduces Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb (NYSE:BMY) Shares Sold by LVW Advisors LLC

Why BioNTech SE (BNTX) Skyrocketed On Monday

Bristol-Myers Squibb Company and BioNTech SE Partner to Advance Next-Gen Cancer Therapies

Adding Neoadjuvant Nivolumab to Chemo Improved Survival in Resectable NSCLC

Bristol Myers' cancer deal is promising, but doesn't change our stance on stock yet

Bristol-Myers (BMY) Licenses BioNTech's Immunotherapy in $11 billion Deal

Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race | Morningstar

Douglas Lane & Associates LLC Sells 48,110 Shares of Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by Milestone Asset Management LLC

Bristol Myers to help develop cancer drug in BioNTech partnership

Bristol Myers to Pay $1.5B for BioNTech Cancer Drug Deal | Newsmax.com

BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types | The Manila Times

BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types | Morningstar

Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Rhumbline Advisers

GAMMA Investing LLC Acquires 2,386,970 Shares of Bristol-Myers Squibb (NYSE:BMY)

This Week in Chancery Court: Squarespace, Bristol-Myers Squibb

BioNTech, Bristol Myers Ink Strategic Partnership To Co-Develop BNT327 For Several Solid Tumor Type

Biontech trades half of bispecific BNT-327 to BMS for potential $11B+ | BioWorld

Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN) and Bristol-Myers Squibb (BMY) | Markets Insider

Longitudinal and multisite sampling reveals mutational and copy number evolution in tumors during metastatic dissemination

Immunotherapy Drugs Show Major Progress in Early-Stage Cancer

Meyer Handelman Co. Sells 7,905 Shares of Bristol-Myers Squibb (NYSE:BMY)

Wealth Enhancement Advisory Services LLC Purchases 120,192 Shares of Bristol-Myers Squibb (NYSE:BMY)

Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial

Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase II NeoCOAST-2 trial

Bristol-Myers Squibb (NYSE:BMY) Stock Price Up 1% - Here's What Happened

Webster Bank N. A. Cuts Stake in Bristol-Myers Squibb (NYSE:BMY)

Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial

Why the stock rally fizzled - plus, our latest thinking on Goldman and Bristol Myers

C3.ai, Inc. (NYSE:AI) Q4 2025 Earnings Call Transcript

Fairtree Asset Management Pty Ltd Invests $550,000 in Bristol-Myers Squibb (NYSE:BMY)

Chancellor Financial Group WB LP Purchases Shares of 8,673 Bristol-Myers Squibb (NYSE:BMY)

111 Capital Purchases New Holdings in Bristol-Myers Squibb (NYSE:BMY)

Two Sigma Investments LP Sells 4,635,617 Shares of Bristol-Myers Squibb (NYSE:BMY)

Rutgers student's internship at Goldman Sachs leads to full-time job offer | Morningstar

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications | Morningstar

Bristol Myers Gets European Approval for Subcutaneous Opdivo | Morningstar

Halozyme Says Bristol-Myers Squibb Gets EC Approval For Opdivo SC Developed With Halozyme's ENHANZE

Top Startup and Tech Funding News - May 27, 2025

Leigh Baldwin & CO. LLC Makes New $534,000 Investment in Bristol-Myers Squibb (NYSE:BMY)

294,400 Shares in Bristol-Myers Squibb (NYSE:BMY) Purchased by Polar Asset Management Partners Inc.

Forum Financial Management LP Acquires 5,462 Shares of Bristol-Myers Squibb (NYSE:BMY)

Ascent Group LLC Increases Position in Bristol-Myers Squibb (NYSE:BMY)

49,748 Shares in Bristol-Myers Squibb (NYSE:BMY) Purchased by GF Fund Management CO. LTD.

Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial

Is It Crohn's or Ulcerative Colitis? IBD Types Are Similar but Not the Same

Hall Capital Management Co. Inc. Purchases Shares of 5,815 Bristol-Myers Squibb (NYSE:BMY)

10,000 Shares in Bristol-Myers Squibb (NYSE:BMY) Purchased by Aurdan Capital Management LLC

Leigh Baldwin & CO. LLC Takes Position in Bristol-Myers Squibb (NYSE:BMY)

846 Shares in Bristol-Myers Squibb (NYSE:BMY) Acquired by Fourth Dimension Wealth LLC

Vise Technologies Inc. Has $2.54 Million Holdings in Bristol-Myers Squibb (NYSE:BMY)

JT Stratford LLC Buys 22,929 Shares of Bristol-Myers Squibb (NYSE:BMY)

Inspire Trust Co. N.A. Sells 45,500 Shares of Bristol-Myers Squibb (NYSE:BMY)

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Increases Stake in Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb (NYSE:BMY) Stock Holdings Decreased by Public Employees Retirement System of Ohio

Week ahead: Magnificent 7 earnings, 2 key inflation reports

Week ahead: Earnings bonanza, ECB decision & US inflation

Week ahead: Megacap tech and 1-in-3 Dow components set to report

Week ahead: Fed to hike 100bps into a recession?

Stellar (XLM) Price Analysis: Where could XLM go in the upcoming days?

Crypto News Today: Bitcoin Price Down 1.85% as US PPI Rises

Dogecoin Price Prediction: Could Dogecoin Price Surge to $0.95?

Morning Note: Middle East Conflict Shakes Markets as Oil Soars, While AI Sector Eyes Growth

Crypto Market Sentiment: Crypto Fear and Greed Index Today

Morning Note: Adobe’s AI Momentum Leads Market Moves with Gold and Fed in Focus

BTC USD Price Prediction: How much will Bitcoin be worth in 2030?

Wells Fargo Stock Slides 1.32%: Is Wells Fargo stock a good buy now?